RFG Advisory LLC Sells 15,980 Shares of Novo Nordisk A/S $NVO

RFG Advisory LLC lowered its holdings in Novo Nordisk A/S (NYSE:NVO) by 29.6% during the fourth quarter, HoldingsChannel.com reports. The fund owned 37,988 shares of the company’s stock after selling 15,980 shares during the period. RFG Advisory LLC’s holdings in Novo Nordisk A/S were worth $1,933,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Guerra Advisors Inc bought a new stake in Novo Nordisk A/S in the third quarter valued at about $25,000. WealthCollab LLC increased its stake in Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after acquiring an additional 260 shares during the period. American National Bank & Trust bought a new stake in Novo Nordisk A/S in the fourth quarter valued at about $28,000. Maseco LLP bought a new stake in Novo Nordisk A/S in the fourth quarter valued at about $29,000. Finally, Jackson Grant Investment Advisers Inc. bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth about $29,000. Institutional investors own 11.54% of the company’s stock.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Q1 beat and guidance lift—Novo posted stronger‑than‑expected results and raised its 2026 outlook after Wegovy pill sales outperformed, which is the main driver of the stock rise. Novo Nordisk’s first-quarter profit beats forecasts
• Positive Sentiment: Oral Wegovy momentum—Prescriptions for the oral Wegovy pill surpassed 2 million since launch, prompting analysts and the company to lift sales/profit guidance and restoring investor confidence in growth prospects. A Look At Novo Nordisk Valuation After Oral Wegovy Success
• Positive Sentiment: Distribution expansion via Amazon—Amazon Pharmacy and One Medical kiosks will offer same‑day delivery/pickup for Novo’s oral GLP‑1s, reducing access friction and likely supporting prescription volume. Amazon Pharmacy Expands Access to New Ozempic® Pill
• Neutral Sentiment: Management pursuing M&A—CEO says Novo is actively seeking deals to broaden the pipeline; positive for long‑term diversification but not an immediate earnings driver. Novo Nordisk actively seeking deals to expand pipeline
• Neutral Sentiment: Regulatory tailwinds possible—the FDA’s recent proposal could benefit leaders in the GLP‑1 space, but policy details and timing remain uncertain. What the FDA’s Latest Proposal Means for Lilly, Novo, and Hims
• Negative Sentiment: Competitive & generic risk—analysts warn that Eli Lilly competition and the arrival of semaglutide generics (first seen in Canada and a threat internationally) could pressure pricing and international revenue over time. First Ozempic generics in Canada will be a test case for Novo Nordisk
• Negative Sentiment: Margin & pricing pressure—despite volume gains, U.S. pricing pressure and some margin compression were noted in Q1 commentary, keeping near‑term profitability under scrutiny. Novo Nordisk: Mixed Q1 Does Not Break The Thesis

Novo Nordisk A/S Stock Up 0.0%

NVO opened at $45.78 on Friday. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $81.44. The firm’s 50-day simple moving average is $38.71 and its 200-day simple moving average is $46.97. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The firm has a market cap of $204.39 billion, a price-to-earnings ratio of 10.75, a PEG ratio of 10.86 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 66.00%. The firm had revenue of $10.85 billion for the quarter. Equities research analysts anticipate that Novo Nordisk A/S will post 3.34 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on NVO shares. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Citigroup started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating on the stock. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Weiss Ratings lowered shares of Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Novo Nordisk A/S in a report on Thursday, February 5th. Four investment analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Novo Nordisk A/S has an average rating of “Hold” and an average target price of $65.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.